Navigation Links
First compound that specifically kills cancer stem cells found
Date:8/13/2009

The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all. Researchers reporting online on August 13th in the journal Cell, a Cell Press publication, have discovered the first compound that targets those cancer stem cells directly.

"It wasn't clear it would be possible to find compounds that selectively kill cancer stem cells," said Piyush Gupta of the Massachusetts Institute of Technology (MIT) and the Broad Institute. "We've shown it can be done."

The team including MIT's Robert Weinberg and the Broad Institute's Eric Lander developed a new high-throughput screening method that makes it possible for the first time to systematically look for agents that kill cancer stem cells. That ability had previously eluded researchers due to the rarity of those cells within tumor cell populations and their relative instability in laboratory culture.

In the new study, the researchers manipulated cultured breast cancer cells to greatly enrich for those with the stem-like properties, including increased resistance to standard cancer drugs. They then screened a library of 16,000 natural and commercial chemical compounds for their ability to kill those stem-like cells and not other cancer cells. That screen turned up 32 contenders.

The researchers narrowed that list down to a handful of chemicals that they could readily get in sufficient quantities for further testing on normal cancer stem cells. Of those, one called salinomycin was the clear winner.

Salinomycin reduced the proportion of breast cancer stem cells by more than 100-fold compared to a commonly used chemotherapeutic drug for breast cancer called paclitaxel (aka Taxol). Salinomycin-treated cells were less able than paclitaxel-treated ones to seed tumors when injected into mice, they report. Salinomycin treatment also slowed the growth of the animals' tumors.

Studies of salinomycin-treated human breast tumors also showed a loss in the activity of genes associated with cancer stem cells.

Exactly how salinomycin's works against cancer stem cells, the researchers don't yet know. As its name suggests, the chemical has antibiotic properties that likely aren't relevant to its newfound cancer stem cell-killing ability. It also disturbs cells' potassium balance.

It remains unclear whether salinomycin itself might find its way to the clinic, Gupta said, since many pharmaceutical steps are involved in the drug discovery process. Nevertheless, the chemical does serve as an immediate tool for manipulating cancer stem cell numbers and observing the effects on cancer's spread and progression.

The findings also highlight a new avenue for the development of cancer therapies, the researchers say.

" To date, rational cancer therapies have been designed to target specific genetic alterations present within tumors," they wrote. "The findings here indicate that a second approach may also prove usefulnamely, searching for agents that target specific states of cancer cell differentiation. Accordingly, future therapies could offer greater possibilities for individualized treatment by considering both the genetic alterations and differentiation states present within the cancer cells of a tumor at the time of diagnosis."

They envision a future in which combination therapies might couple more traditional cancer drugs with those designed to hit the cancer stem cells that would otherwise get left behind.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2017)... ... July 29, 2017 , ... Sunshine Coast ... treatment programs in British Columbia, Canada, is proud to announce it has achieved ... as a form of public outreach to showcase its innovative non-12 step methodology ...
(Date:7/28/2017)... ... July 28, 2017 , ... Mirror Mirror ... Crystal Rewards Program, the most successful CoolSculpting practices across the country are annually ... has achieved the coveted Diamond Level status, the highest ranking possible. , ...
(Date:7/28/2017)... ... July 28, 2017 , ... The Military Family Initiative (MFI), ... announced the grant recipients of its inaugural community outreach grant program. , ... , Falcon’s Landing Chapter, Sterling, Va.: $5,000. Community Veterans Collaboration. , ...
(Date:7/28/2017)... ... July 28, 2017 , ... The Aesthetic Surgery Center ... in the “2017 Best Plastic/Cosmetic Surgeon” category. Dr. Anurag Agarwal, Dr. Richard Maloney, ... The SWFL Choice Awards directly reflect the opinion of Florida residents and is sponsored ...
(Date:7/28/2017)... ... July 28, 2017 , ... Nominated ... Supply Chain Partners for 2017. MEBC received numerous client nominations from customers ... Brad Berger, SupplyChainBrain’s publisher, says “For 15 years running, SupplyChainBrain has published our ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... 2017  Endo International plc (NASDAQ: ENDP ... of its manufacturing network, the Company will be ceasing ... Huntsville, Alabama . The closure of ... next 12 to 18 months. The Huntsville ... of commoditized products and these restructuring actions are intended ...
(Date:7/20/2017)...  Prime Therapeutics LLC (Prime) released this statement from its ... Institute for Clinical and Economic Review,s (ICER) public meeting ... value of abuse-deterrent formulations (ADF) of opioids. Prime was the ... meeting. "The ICER ... the use of abuse-deterrent formulations (ADF) in opioids in terms ...
(Date:7/17/2017)... -- MedX Holdings, Inc., the manufacturer and global distributor of ... today announced the national roll out of its MedX ... standard for the treatment of low back injuries and ... How it works: MedX ... who prescribe the MedX Home Back Machine Program for ...
Breaking Medicine Technology: